Fundraising Fox
Engimmune Therapeutics
Founded 2021 · 12 employees on LinkedIn · 2 known investors
Find your way into Engimmune Therapeutics
Sign up to see every warm intro you have to Engimmune Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Engimmune Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.
Founders & leadership
Engimmune Therapeutics was founded in 2021 by Rodrigo Vazquez-Lombardi and Sai Reddy.
Investors · 2
How we know: Pureos Bioventures's portfolio page · the company's own site · a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeedMay 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Engimmune Therapeutics do?
- Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.
- Who founded Engimmune Therapeutics?
- Engimmune Therapeutics was founded by Rodrigo Vazquez-Lombardi, Sai Reddy in 2021.
- Who are Engimmune Therapeutics's investors?
- Engimmune Therapeutics's investors include Pureos Bioventures, Novo Holdings.